5 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow PTR 3173: new trials by email Literature Review of PTR 3173 trials Research Report on PTR 3173
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics saline, DG3173, octreotide - Acromegaly | Phase 2 | Completed | Aspireo Pharmaceuticals Limited | 8 | 2013-11-01 | 2018-02-15 |
| Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. octreotide, DG3173 - Acromegaly | Phase 2 | Completed | Aspireo Pharmaceuticals Limited | 20 | 2012-10-01 | 2018-02-15 |
| Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173 DG3173, DG3173+Octreotide, Octreotide - Healthy | Phase 1 | Completed | Aspireo Pharmaceuticals Limited | 42 | 2012-04-01 | 2014-08-15 |
| Single Ascending Dose Tolerability Study of DG3173 DG3173, Placebo - Healthy | Phase 1 | Completed | Aspireo Pharmaceuticals Limited | 72 | 2008-05-01 | 2014-08-15 |
| Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173 DG3173, Saline, Octreotide - Healthy | Phase 1 | Completed | Aspireo Pharmaceuticals Limited | 8 | 2014-08-19 |
Acromegaly (2)